Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Equity: 2014-2025

Historic Return on Equity for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to 5.20%.

  • Coherus Oncology's Return on Equity rose 718.00% to 5.20% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.20%, marking a year-over-year increase of 718.00%. This contributed to the annual value of -0.18% for FY2024, which is 161.00% down from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Return on Equity is 5.20%, which was up 129.15% from -17.85% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Equity registered a high of 45.80% during Q2 2022, and its lowest value of -17.85% during Q2 2025.
  • In the last 3 years, Coherus Oncology's Return on Equity had a median value of -0.06% in 2024 and averaged -1.42%.
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 4,696bps in 2022, then crashed by 4,437bps in 2023.
  • Over the past 5 years, Coherus Oncology's Return on Equity (Quarterly) stood at -2.51% in 2021, then soared by 500bps to 2.49% in 2022, then tumbled by 103bps to 1.45% in 2023, then crashed by 552bps to -4.07% in 2024, then soared by 718bps to 5.20% in 2025.
  • Its Return on Equity was 5.20% in Q3 2025, compared to -17.85% in Q2 2025 and -1.70% in Q1 2025.